Those who registered low in angiogenesis gene expression predictably did not benefit as much, and there is a suggestion that mRCC patients harboring low tumor angiogenesis gene expression signatures represent an immune-enriched subtype that is less likely to respond to anti-VEGF therapy alone and may benefit more from strategies involving ICB. This evidence concerns the gene VEGFA and neoplasm.